International Stem Cell (ISCO) Non-Current Debt (2019 - 2020)
International Stem Cell's (ISCO) quarterly Non-Current Debt came in at $2.5 million in Q4 2020, up 4.43% year-over-year from $2.4 million in Q1 2020, and up 4.43% quarter-over-quarter from $2.4 million in Q4 2019.
Powered by 
Analysis
International Stem Cell (ISCO) Non-Current Debt (2019 - 2020) Analysis & Trends
International Stem Cell (ISCO) has reported Non-Current Debt for 2 consecutive years, with $2.5 million the latest figure, recorded in Q4 2020.
- On a quarterly basis, Non-Current Debt rose 4.43% year-over-year to $2.5 million in Q4 2020; TTM through Dec 2020 was $2.5 million, a 4.43% increase from a year earlier, with the FY2020 full-year figure at $2.5 million, up 4.43% from the prior year.
- Non-Current Debt was $2.5 million for Q4 2020 at International Stem Cell, up from $2.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $2.5 million in Q4 2020 and troughed at $2.4 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | International Stem Cell | 2.84 Mn | 1.75 Mn | 1.46 Mn | - |